These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

378 related articles for article (PubMed ID: 32195186)

  • 1. Real-World Data of Triplet Combination of Trastuzumab, Lapatinib, and Chemotherapy in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Gong C; Lu Q; Zhou Z; Luo T; Li W; Li G; Ge R; Xu F; Wang B
    Front Oncol; 2020; 10():271. PubMed ID: 32195186
    [No Abstract]   [Full Text] [Related]  

  • 2. Efficacy of lapatinib combined with capecitabine in patients with HER2-positive metastatic breast cancer in a real-world study.
    Gui X; Li H; Yan Y; Zhang R
    Oncol Lett; 2020 Dec; 20(6):378. PubMed ID: 33154776
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Pyrotinib Combined With Vinorelbine in HER2-Positive Metastatic Breast Cancer: A Multicenter Retrospective Study.
    Li Y; Qiu Y; Li H; Luo T; Li W; Wang H; Shao B; Wang B; Ge R
    Front Oncol; 2021; 11():664429. PubMed ID: 33996589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Primary results of ELAINA: a randomized, multicenter, open-label, phase III study of the efficacy and safety of trastuzumab emtansine
    Wang X; Li W; Yin Y; Tong Z; Zhang Q; Zheng H; Shao Z; Li H; Yang J; Feng J; Wu F; Lamour F; Restuccia E; Jiang Z
    Transl Breast Cancer Res; 2023; 4():3. PubMed ID: 38751488
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Real-world data of triplet combination of pyrotinib, trastuzumab, and chemotherapy in HER2-positive metastatic breast cancer: a multicenter, retrospective study.
    You S; Sang D; Xu F; Luo T; Yuan P; Xie Y; Wang B
    Ther Adv Med Oncol; 2023; 15():17588359231217972. PubMed ID: 38145113
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Real-World Data of Pyrotinib-Based Therapy in Metastatic HER2-Positive Breast Cancer: Promising Efficacy in Lapatinib-Treated Patients and in Brain Metastasis.
    Lin Y; Lin M; Zhang J; Wang B; Tao Z; Du Y; Zhang S; Cao J; Wang L; Hu X
    Cancer Res Treat; 2020 Oct; 52(4):1059-1066. PubMed ID: 32340083
    [TBL] [Abstract][Full Text] [Related]  

  • 7. A retrospective, multicenter study of the efficacy of lapatinib plus trastuzumab in HER2-positive metastatic breast cancer patients previously treated with trastuzumab, lapatinib, or both: the Trastyvere study.
    Gavilá J; De La Haba J; Bermejo B; Rodríguez-Lescure Á; Antón A; Ciruelos E; Brunet J; Muñoz-Couselo E; Santisteban M; Rodríguez Sánchez CA; Santaballa A; Sánchez Rovira P; García Sáenz JÁ; Ruiz-Borrego M; Guerrero-Zotano AL; Huerta M; Cotes-Sanchís A; Lao Romera J; Aguirre E; Cortés J; Llombart-Cussac A
    Clin Transl Oncol; 2020 Mar; 22(3):420-428. PubMed ID: 31203575
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Efficacy and safety of oral pyrotinib in HER2 positive metastatic breast cancer: real-world practice].
    Song GH; Li HP; DI LJ; Yan Y; Jiang HF; Xu L; Wan DG; Li Y; Wang MP; Xiao Y; Zhang RY; Ran R; Wang H
    Beijing Da Xue Xue Bao Yi Xue Ban; 2020 Apr; 52(2):254-260. PubMed ID: 32306007
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Efficacy and safety of margetuximab plus chemotherapy
    Zhang Q; Ouyang Q; Li W; Chiu J; Yan M; Lu YS; Sun S; Li H; Du Y; Wang X; Sun T; Yin Y; Wang H; Ye F; Shen K; Wang J; Pan Y; Wang S; Yang J; Wu X; Dai MS; Cheng J; Teng Y; Su F; Wu X; He J; Fu P; Yang L; Xin Y; Wang X; Jiang Z
    Transl Breast Cancer Res; 2022; 3():31. PubMed ID: 38751523
    [TBL] [Abstract][Full Text] [Related]  

  • 10. A randomized phase II trial of trastuzumab plus capecitabine versus lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer previously treated with trastuzumab and taxanes: WJOG6110B/ELTOP.
    Takano T; Tsurutani J; Takahashi M; Yamanaka T; Sakai K; Ito Y; Fukuoka J; Kimura H; Kawabata H; Tamura K; Matsumoto K; Aogi K; Sato K; Nishio K; Nakagawa K; Saeki T
    Breast; 2018 Aug; 40():67-75. PubMed ID: 29698927
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Comparing pyrotinib with trastuzumab and pertuzumab with trastuzumab for HER2-positive metastatic breast cancer: a retrospective, multicenter analysis.
    You S; Xie Y; Sang D; Luo T; Yuan P; Xu F; Wang B
    Front Endocrinol (Lausanne); 2023; 14():1325540. PubMed ID: 38149099
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Trastuzumab emtansine versus capecitabine plus lapatinib in patients with previously treated HER2-positive advanced breast cancer (EMILIA): a descriptive analysis of final overall survival results from a randomised, open-label, phase 3 trial.
    Diéras V; Miles D; Verma S; Pegram M; Welslau M; Baselga J; Krop IE; Blackwell K; Hoersch S; Xu J; Green M; Gianni L
    Lancet Oncol; 2017 Jun; 18(6):732-742. PubMed ID: 28526536
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Oral vinorelbine in combination with trastuzumab as a first-line therapy of metastatic or locally advanced HER2-positive breast cancer.
    Farhat F; Kattan JG; Ghosn M
    Cancer Chemother Pharmacol; 2016 May; 77(5):1069-77. PubMed ID: 27059339
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Trastuzumab-based Retreatment after Lapatinib in Heavily Pretreated HER2 Positive Metastatic Breast Cancer: an Anatolian Society of Medical Oncology Study.
    Uncu D; Bayoglu IV; Arslan UY; Kucukoner M; Artac M; Koca D; Oguz A; Demirci U; Arpaci E; Dogan M; Kucukzeybek Y; Turker I; Isikdogan A; Guler T; Zengin N
    Asian Pac J Cancer Prev; 2015; 16(9):4127-31. PubMed ID: 25987098
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Real-world data of lapatinib and treatment after lapatinib in patients with previously treated HER2-positive metastatic breast cancer: A multicenter, retrospective study.
    Xie Y; Ge R; Sang D; Luo T; Li W; Ji X; Yuan P; Wang B
    Cancer Med; 2020 May; 9(9):2981-2988. PubMed ID: 32108439
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A phase II study of trastuzumab emtansine in patients with human epidermal growth factor receptor 2-positive metastatic breast cancer who were previously treated with trastuzumab, lapatinib, an anthracycline, a taxane, and capecitabine.
    Krop IE; LoRusso P; Miller KD; Modi S; Yardley D; Rodriguez G; Guardino E; Lu M; Zheng M; Girish S; Amler L; Winer EP; Rugo HS
    J Clin Oncol; 2012 Sep; 30(26):3234-41. PubMed ID: 22649126
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effectiveness and safety of pyrotinib-based therapy in patients with HER2-positive metastatic breast cancer: A real-world retrospective study.
    Li C; Bian X; Liu Z; Wang X; Song X; Zhao W; Liu Y; Yu Z
    Cancer Med; 2021 Dec; 10(23):8352-8364. PubMed ID: 34672424
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Lapatinib plus capecitabine in patients with HER2-positive metastatic breast cancer: A systematic review
.
    Madden R; Kosari S; Peterson GM; Bagheri N; Thomas J
    Int J Clin Pharmacol Ther; 2018 Feb; 56(2):72-80. PubMed ID: 29231164
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Pertuzumab in combination with trastuzumab and chemotherapy for Chinese patients with HER2-positive metastatic gastric or gastroesophageal junction cancer: a subpopulation analysis of the JACOB trial.
    Liu T; Qin Y; Li J; Xu R; Xu J; Yang S; Qin S; Bai Y; Wu C; Mao Y; Wu H; Ge Y; Shen L
    Cancer Commun (Lond); 2019 Jun; 39(1):38. PubMed ID: 31234927
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Randomised Phase 2 study of lapatinib and vinorelbine vs vinorelbine in patients with HER2 + metastatic breast cancer after lapatinib and trastuzumab treatment (KCSG BR11-16).
    Sim SH; Park IH; Jung KH; Kim SB; Ahn JH; Lee KH; Im SA; Im YH; Park YH; Sohn J; Kim YJ; Lee S; Kim HJ; Chae YS; Park KH; Nam BH; Lee KS; Ro J
    Br J Cancer; 2019 Dec; 121(12):985-990. PubMed ID: 31690831
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.